In 2014, Sapien partnered with Oncostem Diagnostics to provide our curated breast cancer FFPE blocks and RWE 5 years treatment and recurrence outcome data to enable the validation of a new test to accurately determine the risk of recurrence in early stage breast ca patients. A key goal of the test was to identify patients at low risk that could avoid chemotherapy and its side-effects, a major benefit to #cancerpatients (see Sapien referenced in this & previous papers).
It’s gratifying to see their first test, canAssist Breast for hormone positive breast cancer patients, perform equivalent to the gold standard Oncotype Dx test, a more expensive and higher TAT for Indian patients.
Our deep collection of matched FFPE blocks and longitudinal RWE data to enable precision medicine tests has continued to grow, both in breast cancer (>10,000 cases), and in #colorectalcancer, #lungcancer, #oralcancer, #kidneycancer, #ovariancancer #glioma #liver cancers. Contact us at firstname.lastname@example.org